<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391831</url>
  </required_header>
  <id_info>
    <org_study_id>NatHis-SMA</org_study_id>
    <secondary_id>IDRCB-2014-A01263-44</secondary_id>
    <nct_id>NCT02391831</nct_id>
  </id_info>
  <brief_title>Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy</brief_title>
  <acronym>NatHis-SMA</acronym>
  <official_title>Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Myologie, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Roche de Recherche et Médecine Translationnelle</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Myologie, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NatHis-SMA is a prospective, longitudinal and interventional study of the natural history of
      patients with type 2 and 3 Spinal Muscular Atrophy (SMA). The purpose of this study is to
      characterize the disease course over 2 years and identify prognostic variables of the disease
      and biomarkers of SMA progression, as well as determine the best outcome measures for further
      therapeutics approaches.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of muscle strength</measure>
    <time_frame>Baseline and then every 6 months until end of the study, up to 24 months</time_frame>
    <description>Study-specific assessments: Grip and pinch strength</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of motor function</measure>
    <time_frame>Baseline and then every 6 months until end of the study, up to 24 months</time_frame>
    <description>Study-specific assessments: Moviplate and MFM scores, upper extremity functional reaching volume, timed tests (time to rise from floor, time to walk 10 meters, time to climb and descend stairs, distance walked on the Six-Minute Walk Test)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of respiratory function</measure>
    <time_frame>Baseline and then every 6 months until end of the study, up to 24 months</time_frame>
    <description>Study-specific assessments: Pulmonary function tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of physical activity of upper limbs movements</measure>
    <time_frame>Baseline and then every 6 months until end of the study, up to 24 months</time_frame>
    <description>Quantity and duration of movements, time of inactivity during the day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of skeletal muscle nuclear magnetic resonance (NMR) imaging (MRI)</measure>
    <time_frame>Baseline and then every 12 months until the end of the study, up to 24 months</time_frame>
    <description>Muscle volume changes, intramuscular fatty infiltration progression, indices of disease activity (only for Paris and Strasbourg sites and for patients older than 4 years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of electrophysiology measurements</measure>
    <time_frame>Baseline and then every 6 months until end of the study, up to 24 months</time_frame>
    <description>Compound Motor Action Potential (CMAP) Amplitude and Decrement search</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Biomarkers of SMA progression</measure>
    <time_frame>Baseline and then every 6 months until end of the study, up to 24 months</time_frame>
    <description>SMN mRNA and protein analysis, SMA exploratory biomarkers (e.g. mRNA, DNA profiling, RNA profiling, proteomic profiling)</description>
  </secondary_outcome>
  <enrollment type="Actual">81</enrollment>
  <condition>Type 2 Spinal Muscular Atrophy</condition>
  <condition>Type 3 Spinal Muscular Atrophy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Strength, function and activity measurements</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Muscle MRI</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electrophysiology measurements</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling for biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  Type 2 or 3 spinal muscular atrophy genetically confirmed

          -  Age superior or equal to 2 years old up to 30 years of age included

          -  For patients older than 6 years old, willing and able to comply with all protocol
             requirements and procedures.

          -  For non-ambulant patients, able to sit upright in a wheelchair for at least three
             hours

          -  Patients over 18 years of age and parent(s)/legal guardian(s) of patients &lt; 18 years
             of age must provide written informed consent prior to participating in the study and
             informed assent will be obtained from minors at least 7 years of age when required by
             regulation.

          -  In France only: Affiliated to or a beneficiary of a social security category

        EXCLUSION CRITERIA

          -  Previously treated with an investigational drug within 6 months prior the recruitment
             in this study.

          -  Other condition which may significantly interfere with the assessment of the SMA and
             is clearly not related to the disease

          -  Current or anticipated participation in any therapeutic investigational clinical
             studies.

          -  Patients with specific contraindication to MRI (i.e. metallic foreign body,
             claustrophobia, and others deemed to be prohibitive by the investigators) will be
             allowed to participate, but MRI will not be performed.

          -  For women : pregnancy or current breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Servais, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Association Institut de Myologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reference centre for neuromuscular diseases - UZ Leuven - Department of Pediatrics - University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Référence neuromusculaire - CHR La Citadelle</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Rééducation Pédiatrique Infantile &quot; L'Escale &quot; - Hôpital Femme Mère Enfant</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maladie Neuromusculaire de l'enfant - Service Maladies infectieuses et neurologie infantile - Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de référence Maladies Neuromusculaires Nantes-Angers - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I-Motion Institute - Trousseau Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropédiatrie - Service de Pédiatrie 1 - CHU Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unité de neurologie pédiatrique - Hôpital des enfants</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen (AöR) - Klinik für Kinderheilkunde I - Sozialpädiatrisches Zentrum</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SMA</keyword>
  <keyword>Spinal Muscular Atrophy</keyword>
  <keyword>Neuromuscular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

